CLVLY Clinuvel Pharms Ltd S/Adr

10.42
-1.78  -15%
Previous Close 12.2
Open 10
Price To Book 13.36
Market Cap 514,855,722
Shares 49,410,338
Volume 67,526
Short Ratio
Av. Daily Volume 8,754
Stock charts supplied by TradingView

NewsSee all news

  1. FDA Approves SCENESSE® For Genetic Disorder

    MELBOURNE, Australia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has approved a new drug as the first ever treatment for a rare genetic metabolic disorder which causes absolute

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced October 8, 2019.
SCENESSE
Phototoxicity and anaphylactoid reactions in adult patients with erythropoietic protoporphyria (EPP)

Latest News

  1. FDA Approves SCENESSE® For Genetic Disorder

    MELBOURNE, Australia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has approved a new drug as the first ever treatment for a rare genetic metabolic disorder which causes absolute